116 related articles for article (PubMed ID: 25353620)
1. Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications.
Abdel-Rahman O
Expert Rev Anticancer Ther; 2015 Feb; 15(2):235-45. PubMed ID: 25353620
[TBL] [Abstract][Full Text] [Related]
2. c-Met targeting in advanced gastric cancer: An open challenge.
Marano L; Chiari R; Fabozzi A; De Vita F; Boccardi V; Roviello G; Petrioli R; Marrelli D; Roviello F; Patriti A
Cancer Lett; 2015 Aug; 365(1):30-6. PubMed ID: 26049023
[TBL] [Abstract][Full Text] [Related]
3. Role of c-mesenchymal-epithelial transition pathway in gastric cancer.
Fioroni I; Dell'Aquila E; Pantano F; Intagliata S; Caricato M; Vincenzi B; Coppola R; Santini D; Tonini G
Expert Opin Pharmacother; 2015 Jun; 16(8):1195-207. PubMed ID: 25881479
[TBL] [Abstract][Full Text] [Related]
4. Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspects.
Abdel-Rahman O
Crit Rev Oncol Hematol; 2015 Jan; 93(1):18-27. PubMed ID: 24970311
[TBL] [Abstract][Full Text] [Related]
5. Recent advances and future trends in the targeted therapy of metastatic gastric cancer.
Al-Batran SE; Werner D
Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):555-69. PubMed ID: 24665840
[TBL] [Abstract][Full Text] [Related]
6. SB365, Pulsatilla saponin D, targets c-Met and exerts antiangiogenic and antitumor activities.
Hong SW; Jung KH; Lee HS; Son MK; Yan HH; Kang NS; Lee J; Hong SS
Carcinogenesis; 2013 Sep; 34(9):2156-69. PubMed ID: 23671132
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy for gastric adenocarcinoma.
Almhanna K
Adv Pharmacol; 2012; 65():437-70. PubMed ID: 22959034
[TBL] [Abstract][Full Text] [Related]
8. Nonsteroidal anti-inflammatory drugs for treatment of advanced gastric cancer: cyclooxygenase-2 is involved in hepatocyte growth factor mediated tumor development and progression.
Chen JH; Liu TY; Wu CW; Chi CW
Med Hypotheses; 2001 Oct; 57(4):503-5. PubMed ID: 11601879
[TBL] [Abstract][Full Text] [Related]
9. Recent updates of precision therapy for gastric cancer: Towards optimal tailored management.
Joo MK; Park JJ; Chun HJ
World J Gastroenterol; 2016 May; 22(19):4638-50. PubMed ID: 27217696
[TBL] [Abstract][Full Text] [Related]
10. The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.
Aprile G; Giampieri R; Bonotto M; Bittoni A; Ongaro E; Cardellino GG; Graziano F; Giuliani F; Fasola G; Cascinu S; Scartozzi M
Expert Opin Investig Drugs; 2014 Jul; 23(7):925-42. PubMed ID: 24806575
[TBL] [Abstract][Full Text] [Related]
11. Clinical management of advanced gastric cancer: the role of new molecular drugs.
De Vita F; Di Martino N; Fabozzi A; Laterza MM; Ventriglia J; Savastano B; Petrillo A; Gambardella V; Sforza V; Marano L; Auricchio A; Galizia G; Ciardiello F; Orditura M
World J Gastroenterol; 2014 Oct; 20(40):14537-58. PubMed ID: 25356019
[TBL] [Abstract][Full Text] [Related]
12. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
13. Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma.
Li Y; Chen CQ; He YL; Cai SR; Yang DJ; He WL; Xu JB; Zan WH
J Surg Oncol; 2012 Sep; 106(3):304-10. PubMed ID: 22231933
[TBL] [Abstract][Full Text] [Related]
14. Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.
Koeppen H; Rost S; Yauch RL
J Pathol; 2014 Jan; 232(2):210-8. PubMed ID: 24105670
[TBL] [Abstract][Full Text] [Related]
15. Suppression of tumor growth, invasion and angiogenesis of human gastric cancer by adenovirus-mediated expression of NK4.
Heideman DA; van Beusechem VW; Bloemena E; Snijders PJ; Craanen ME; Offerhaus GJ; Derksen PW; de Bruin M; Witlox MA; Molenaar B; Meijer CJ; Gerritsen WR
J Gene Med; 2004 Mar; 6(3):317-27. PubMed ID: 15026993
[TBL] [Abstract][Full Text] [Related]
16. Potential role of rilotumumab in the treatment of gastric cancer.
Waddell T; Moorcraft SY; Cunningham D
Immunotherapy; 2014; 6(12):1243-53. PubMed ID: 25524381
[TBL] [Abstract][Full Text] [Related]
17. Extracellular signal-regulated kinase and Akt activation play a critical role in the process of hepatocyte growth factor-induced epithelial-mesenchymal transition.
Tanahashi T; Osada S; Yamada A; Kato J; Yawata K; Mori R; Imai H; Sasaki Y; Saito S; Tanaka Y; Nonaka K; Yoshida K
Int J Oncol; 2013 Feb; 42(2):556-64. PubMed ID: 23229794
[TBL] [Abstract][Full Text] [Related]
18. Gastric cancer: somatic genetics as a guide to therapy.
Zhang XY; Zhang PY
J Med Genet; 2017 May; 54(5):305-312. PubMed ID: 27609016
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapies in the treatment of gastric cancer.
Ngeow J; Tan IB; Choo SP
Asia Pac J Clin Oncol; 2011 Sep; 7(3):224-35. PubMed ID: 21884434
[TBL] [Abstract][Full Text] [Related]
20. [Experimental study of the hepatocyte growth factor contributing to lymphangiogenesis and lymphatic metastasis in gastric cancer].
Zhang QH; Qian K; Li XJ; Pu J; Wu XT
Zhonghua Wei Chang Wai Ke Za Zhi; 2007 May; 10(3):212-6. PubMed ID: 17520376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
